The stock of Chimerix Inc (NASDAQ:CMRX) is a huge mover today! About 290,259 shares traded hands. Chimerix Inc (NASDAQ:CMRX) has declined 2.73% since March 9, 2016 and is downtrending. It has underperformed by 10.14% the S&P500.
The move comes after 9 months negative chart setup for the $212.32M company. It was reported on Oct, 12 by Barchart.com. We have $4.14 PT which if reached, will make NASDAQ:CMRX worth $27.60M less.
Analysts await Chimerix Inc (NASDAQ:CMRX) to report earnings on November, 3. They expect $-0.46 earnings per share, up 34.29% or $0.24 from last year’s $-0.7 per share. After $-0.39 actual earnings per share reported by Chimerix Inc for the previous quarter, Wall Street now forecasts 17.95% negative EPS growth.
Chimerix Inc (NASDAQ:CMRX) Ratings Coverage
Out of 7 analysts covering Chimerix Inc (NASDAQ:CMRX), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. Chimerix Inc has been the topic of 16 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Monday, October 5 report. UBS initiated the stock with “Buy” rating in Thursday, December 17 report. The firm has “Neutral” rating given on Tuesday, December 29 by JP Morgan. The stock has “Buy” rating given by Brean Capital on Thursday, August 6. As per Tuesday, February 23, the company rating was downgraded by Morgan Stanley. FBR Capital downgraded the shares of CMRX in a report on Monday, December 28 to “Mkt Perform” rating. On Tuesday, February 23 the stock rating was maintained by FBR Capital with “Mkt Perform”. Piper Jaffray maintained Chimerix Inc (NASDAQ:CMRX) on Monday, December 28 with “Overweight” rating. Barclays Capital maintained it with “Overweight” rating and $12 target price in Tuesday, December 29 report. The firm has “Outperform” rating by FBR Capital given on Tuesday, August 18.
According to Zacks Investment Research, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.27, from 1.07 in 2016Q1. The ratio fall, as 23 funds sold all Chimerix Inc shares owned while 37 reduced positions. 16 funds bought stakes while 32 increased positions. They now own 30.87 million shares or 5.26% less from 32.59 million shares in 2016Q1.
Bnp Paribas Arbitrage has invested 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX). Apriem Advsrs last reported 0% of its portfolio in the stock. The Pennsylvania-based Hamilton Lane Advisors Ltd Liability Co has invested 0.14% in Chimerix Inc (NASDAQ:CMRX). Highbridge Ltd Liability Corporation has 28,656 shares for 0% of their US portfolio. Susquehanna Grp Inc Limited Liability Partnership has 0% invested in the company for 44,290 shares. Checchi Advisers Limited Company last reported 0% of its portfolio in the stock. New York State Common Retirement Fund has 0% invested in the company for 23,800 shares. Jpmorgan Chase accumulated 0% or 43,774 shares. Wells Fargo & Mn reported 17,275 shares or 0% of all its holdings. Fmr Ltd Liability Company last reported 0% of its portfolio in the stock. Goldman Sachs Group holds 68,098 shares or 0% of its portfolio. Axa holds 138,980 shares or 0% of its portfolio. Redmile Lc, a California-based fund reported 3.29 million shares. Farallon Cap Management Llc last reported 593,138 shares in the company. Glenmede Na reported 6,992 shares or 0% of all its holdings.
Insider Transactions: Since May 10, 2016, the stock had 3 insider buys, and 1 insider sale for $241,560 net activity. MARIO ERNEST also bought $45,328 worth of Chimerix Inc (NASDAQ:CMRX) on Friday, May 13. Berrey M Michelle bought $100,226 worth of Chimerix Inc (NASDAQ:CMRX) on Monday, August 29. On Thursday, September 15 the insider LEONARD JOHN M. sold $25,163.
More recent Chimerix Inc (NASDAQ:CMRX) news were published by: Fool.com which released: “Here’s Why Chimerix Inc Jumped 14.3% in April” on May 06, 2016. Also Fool.com published the news titled: “Why Chimerix Inc. Is Up Big Today” on January 19, 2016. Valuewalk.com‘s news article titled: “Chimerix, Inc. (CMRX)Tanks After Report Of Failed Late State Trial” with publication date: December 28, 2015 was also an interesting one.
CMRX Company Profile
Chimerix, Inc. (Chimerix), incorporated on April 7, 2000, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.